Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Description

Primary Objectives

• To determine the 6-month circulating tumor (ctDNA) clearance rate following 6 months of therapy with RELO regimen in patients with colorectal cancer (CRC) who present with radiographic occult molecular residual disease (MRD) after completing definitive standard-of-care (SOC) therapy.

Secondary Objectives

* To determine the 3-month ctDNA clearance rate following RELO treatment.
* To determine disease-free survival (DFS) following 6 months of RELO treatment.
* To determine overall survival (OS) following 6 months of RELO treatment.
* To determine the safety and tolerability of RELO.